VistaGen Therapeutics, Inc. (VSTA) to Profit from Growing Need for Better Approach
A recent article by Ryan McBride in biotech industry newsletter FierceBiotech (http://dtg.fm/i12W) highlights a major transition that needs to occur in the pharmaceutical industry. The article points to a speech by Ken Kaitin, director of the Tufts Center for the Study of Drug Development, suggesting that drug development companies need to fix broken areas of development that are costing them billions of dollars from unnecessary procedures in clinical trials. Kaitin’s group expects pharma to replace traditional trial-and-error testing methods with newer approaches, such as biomarkers, modeling, and simulation, all in an effort to reduce failures and associated costs, costs which…